†Some patients were treated with a three-injection Synvisc regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.
Synvisc and Synvisc-One are registered trademarks of Genzyme Biosurgery.
DUROLANE Offers Longer Lasting Knee Pain Relief vs Steroid.4
Summary of Indications for Use
DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.
Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.
DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com, or by contacting Bioventus Customer Service at 1-800-836-4080.
DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
NASHA is a registered trademark of Nestlé Skin Health S.A.
Osteoarthritis: The Ongoing Challenges to Manage Pain